Navigation Links
Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Date:6/30/2008

Company Announces Revised Operating Plan to Respond to NEBIDO Delay

LEXINGTON, Mass., June 30 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for NEBIDO(R) related to a New Drug Application (NDA) submitted to the FDA in August 2007. The letter, received on June 27, 2008, indicated that the application may be approved if the Company is able to adequately respond to certain clinical deficiencies related to the product. The letter generally confirmed the Company's previously-announced indications from the FDA based on telephone discussions.

The FDA has expressed a concern about a relatively small number of patients in European post-marketing use who have experienced respiratory symptoms immediately following the intramuscular injection of NEBIDO 1000 mg, 4 cc injection volume, (versus the 750 mg, 3 cc injection volume used in the United States). The Company believes and the FDA concurs that the reaction is likely the result of a small amount of the oily solution immediately entering the vascular system from the injection site, a known, rare complication of oil-based depot injections.

The phenomenon is characterized by short-term reactions involving an urge to cough, coughing episodes or a shortness of breath. In rare cases the reaction has been classified as serious or the patient experiences other symptoms such as dizziness, flushing or fainting. In the Company's U.S. clinical trials of NEBIDO 750 mg (3 cc injection volume), the proposed dose in the U.S., there was a single, mild, non-serious case of oil-based cough observed. In addition, the FDA believes that four cases in the European post-
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Indevus Announces Management Changes
2. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
3. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
4. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
7. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
8. Indevus Announces Allergan as New Partner for SANCTURA Brand
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. Alfacell Receives NASDAQ Non-Compliance Notification
11. Albany College of Pharmacy Researcher Receives $368,445 Grant from the National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/30/2015)... ... 2015 , ... As part of its 2015 growth plan and as a follow up to ... business units, Whitehouse Laboratories is pleased to announce that it has begun construction on a ... Excellence and will be strictly dedicated to basic USP 51, USP 61, and USP 62 ...
(Date:7/29/2015)... 30, 2015 Sanofi, un ... ses résultats pour le premier semestre 2015. Le ... résultats. Visionner l,interview vidéo et lire ... Au sommaire de l,interview :  ... de croissance - Diabète ...
(Date:7/29/2015)... (Q2 2015: +14% CER / 20% of sales) led the regional performance in ... , as well as solid contributions from Korea, India ... Middle East / Africa (Q2 2015: ... , Turkey and the United Kingdom ... excluding U.S. HPV sales, on demand across all customer classes. The top seven ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10
... regulatory approvals for the $2.3 billion acquisition of Instrumentarium ... of two divisions of the company they are acquiring. ... plans to integrate Instrumentarium it into its GE ... Dow Wilson.. , ,The final required regulatory ...
... Network ready to air a sitcom set in mythical Waterford ... prime-time televisions limelight whether it wants to or not. ... stars Norm Macdonald of Saturday Night Live and Norm fame, ... review of the show makes it sound like a neurotic ...
... MADISON, WI - Even as the State Assembly Ways and ... -- a measure that would end state and local sales ... was passing a measure that, if it becomes law, would ... passed H.R. 49 , which would permanently extend an ...
Cached Biology Technology:Maybe its time to write our own television shows about Wisconsin 2State and Feds Race to Stop Taxation of Internet Access 2State and Feds Race to Stop Taxation of Internet Access 3State and Feds Race to Stop Taxation of Internet Access 4
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
(Date:7/23/2015)... July 23, 2015 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its second quarter ended June 30, ... 2015 was $4.5 million, a decrease of 33% compared to ... in the second quarter of 2015 was $0.3 million, or ... $0.04 per diluted share, in the same period a year ...
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... ZambiaAccording to a report issued last week by UNAIDS, ... mortality worldwide. But Dr. Groesbeck Parham, gynecologic oncologist ... the Center for Infectious Disease Research in Zambia (CIDRZ) ... up dying of cervical cancer unless they have access ...
... of the Eastern Virginia Medical School today announced that it ... Melinda Gates Foundation to develop microbicides for HIV prevention. ... $65 million to CONRAD for microbicide research. ... research on novel and improved in vitro and small-animal models ...
... new x-ray technique that could be used to detect hidden ... Cernik and colleagues from The School of Materials have built ... each point of an image to be clearly identified. ... The Journal of the Royal Society Interface and is published ...
Cached Biology News:Women with AIDS face cervical cancer threat 2CONRAD receives $28.5M Gates Foundation grant for HIV prevention research 2New X-ray technique targets terrorists and tumors 2
... Essentials Kit provides all the necessary materials and ... mir Vana miRNA Bioarrays when using a ... mir Vana miRNA Labeling Kit. The kit ... BA10001) that should be spiked into your miRNA ...
... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
... siRNA Tracker Intracellular Localization Kit provides a ... deliver siRNA, of your design, in an ... tracking experiments. Subcellular localization and functional inhibition ... following introduction of the labeled siRNA into ...
... Intracellular Localization Kit provides a straight forward ... of your design, in an efficient yet ... Subcellular localization and functional inhibition of target ... of the labeled siRNA into mammalian cells. ...
Biology Products: